ER_PARTNERS

Chromatin Mediators of Estrogen Receptor Biology

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Sito del progetto	http://www.alpha-man.eu/index.htm
Totale costo	1˙500˙345 €
EC contributo	1˙500˙345 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2009-StG
Funding Scheme	ERC-SG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-10-01   -   2014-09-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	CANCER RESEARCH UK  Organization address address: ST JOHN STREET 407 ANGEL BUILDING city: LONDON postcode: EC1V 4AD contact info Titolo: Dr. Nome: Emma Cognome: Ryley Email: send email Telefono: +44 1223 404262 Fax: +44 1223 404199	UK (LONDON)	beneficiary	768˙796.50
2	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Dr. Nome: Jason Scott Cognome: Carroll Email: send email Telefono: +44 1223769649 Fax: +44 1223769510	UK (CAMBRIDGE)	hostInstitution	731˙548.50
3	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +44 1223 333543 Fax: +44 1223 332988	UK (CAMBRIDGE)	hostInstitution	731˙548.50

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Estrogen Receptor (ER) drives proliferation in breast cancers and drugs such as tamoxifen and Aromatase Inhibitors, that target ER activity, are first line treatments in clinical practice. However drug resistance is a significant clinical problem. My laboratory has reported that chromatin-modifying pioneer factors are required for ER to bind the genome, and may constitute a unique opportunity for treating drug resistant cancer. My proposal consists of two complementary approaches to comprehensively explore how Estrogen Receptor interacts with these factors to direct transcription. (1) We will demonstrate that FoxA1 and the Groucho protein TLE1 are critical mediators of ER-chromatin interactions by mapping TLE1 binding sites on a genome-wide basis, and functionally testing the roles these factors play with ER in genomic remodeling, gene transcription, cell proliferation, and endocrine resistance. (2) More globally, to characterise ER transcriptional partners on a molecular basis, we will identify the complete complement of ER-associated proteins using novel proteomic approaches. Taken together, these approaches will explore how ER employs pioneer factors mechanistically, and will identify other potential players.'